European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene
Year: 2014
Type: article
Source: Neuromuscular Disorders
Institutions: European Medicines Agency, Medical Products Agency, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Medicines and Healthcare products Regulatory Agency, Federal Institute for Drugs and Medical Devices, Agencia Española de Medicamentos y Productos Sanitarios, Medicines Evaluation Board
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2005330089
